|
|
 With summer on the way, C+D looks at OTC treatments for bites and stings from common insects and jellyfish, as well as possible future methods of drug delivery through the skin.
Want to learn more about a particular clinical topic? Find relevant Update articles using our new subject index.
 Senior medicines sales assistant Hannah is worried about her mother, who is feeling awful after her GP advised her to stop taking HRT. What should she do?
The MHRA reviewed the safety and efficacy of cough and cold products in children and advised that cough and cold products containing certain active ingredients will no longer be licensed for children under the age of two years.
From 1 April it will be unlawful to sell or supply a product or products containing more than 720mg of pseudoephedrine salts or more than 180mg ephedrine base (or salts) to a person at one time (ie, in one transaction) - sale or supply will require a prescription.
Changes concerning the format of the Controlled Drug Register (CDR) and the headings / titles of columns used to capture the mandatory fields of information will come into force on 1 February 2008. These changes will apply to England, Scotland and Wales.
Pharmacists are advised to note that changes have been made to the legislation regarding the way in which requisitions for Controlled Drugs in Schedules 1, 2 or 3 must be handled.
This Law and Ethics Bulletin forms the second and final part of a series. This bulletin gives information on the submission processes in place for Schedule 1, 2 or 3 Controlled Drug requisitions.
Pharmacists are advised that they must not sell plano (zero powered) cosmetic contact lenses unless they are sold under the supervision of a registered optician, dispensing optician or doctor.
Pharmacists and pharmacy technicians are advised that they must only use their original registration certificate, issued by the Society, to display their registration details in a pharmacy. Under no circumstances may a copy of a registration certificate be used.
Pharmacists are advised that on 1 January 2008, midazolam’s legal classification will change from its current status as a Schedule 4 Part I Controlled Drug to a Schedule 3 Controlled Drug.
| | |
